Home / Business & Investment News / Braincure-Biotech.com Demonstrates Sustained Improvement in Functional Outcomes Sclerosis Patients

Braincure-Biotech.com Demonstrates Sustained Improvement in Functional Outcomes Sclerosis Patients

Related eBooks

Braincure-Biotech.com Demonstrates Sustained Improvement in Functional Outcomes Sclerosis Patients

This post-hoc analysis provides the first evidence that the new treatment is associated with a significant improvement in functional outcome

Online PR News – 09-November-2015 – Braincure-Biotech.com announced that a post-hoc analysis showed in a new and not released treatment increases the probability of achieving sustained improvement in physical disability over two years when compared to placebo. This post-hoc analysis provides the first evidence that the new treatment is associated with a significant improvement in functional outcome, rather than only slowing or preventing progression of disability, in those living with relapsing multiple brain sclerosis.

These results show that patients treated with this new technique are significantly more likely to experience a sustained improvement in disability compared to placebo patients. This finding from a post-hoc analysis of the pivotal trial supports both the earlier findings from the trial that the treatment is associated with an improvement in quality of life as well as anecdotal evidence of recovery of function in some patients. said Liao Ming, MD, Head of Department of Neurology at Braincure Biotech. While other therapies have shown a slowing of progression in disability, this analysis represents the first evidence supporting a sustained improvement in function associated with an approved disease modifying therapy.

The proportion of patients exhibiting sustained improvements in physical disability in the study was determined based upon the Expanded Disability Status Scale (EDSS) over two years in patients with relapsing MS. EDSS is one of the oldest and most widely utilized methods of quantifying disability in MS.
The name of the treatment and the medicine will be made public upon approval.

About Braincure Biotech
Braincure-Biotech.com is a state-of-the-art technology research company that uses discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimers disease, other forms of dementia, and mechanistically similar disorders. Braincure Biotechs strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. The goal of the firm is to discover and develop novel, disease modifying therapies for dementia and mechanistically similar disorders. The highly professional and acclaimed team of scientists maintains an innovative and motivating environment in which every employee has the possibility to contribute to our joint success and to grow individually.

Company Contact Information
Braincure-Biotech-com
http://www.braincure-biotech.com/
+886
 

Check Also

Consider Kirkland Lake Gold (KL), A Gold Mining Growth Stock

This week we are looking at another of the Investor’s Business Daily (IBD) Top 50 List companies.  We use this list in one of our options portfolios to spot outperforming stocks and place option spreads that take advantage of the momentum. Last week was a great one for the market (SPY up 2.6%) and an even better one for the Terry’s Tips 8 actual option portfolios.  Every one made gains, and the composite average picked up 11%, a record we are quite proud of.  Terry Consider Kirkland Lake Gold (KL), A Gold Mining Growth Stock The Investor’s Business Daily recently posted an article which started out by stating “Gold might not come to mind first when you think of growth stocks” which is very true.  Take a look at this article for the full write up and the reasoning behind why they see growth potential in this stock.  Also check out Kirkland Lake Gold Receives Consensus Rating of “Buy” from Analysts.

Leave a Reply

Your email address will not be published. Required fields are marked *

css.php